Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Familial hypertriglyceridemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    13 result(s) found for: Familial hypertriglyceridemia. Displaying page 1 of 1.
    EudraCT Number: 2020-002536-67 Sponsor Protocol Number: ISIS678354-CS3 Start Date*: 2021-04-15
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of AKCEA‑APOCIII‑LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10059183 Familial hypertriglyceridaemia PT
    20.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) NO (Completed) FR (Completed) PT (Completed) SK (Completed) HU (Completed) NL (Ongoing) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003280-95 Sponsor Protocol Number: ISIS678354-CS13 Start Date*: 2022-06-16
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10059183 Familial hypertriglyceridaemia PT
    20.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) NO (Completed) PT (Trial now transitioned) FR (Trial now transitioned) SK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002192-19 Sponsor Protocol Number: ISIS678354-CS5 Start Date*: 2022-07-22
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia
    Medical condition: Severe hypertryglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10059183 Familial hypertriglyceridaemia PT
    20.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) BG (Trial now transitioned) SK (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000872-40 Sponsor Protocol Number: CLCQ908C2201 Start Date*: 2012-11-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A pilot study to assess the efficacy and safety of LCQ908 alone and in combination with fenofibrate or Lovaza® in patients with severe hypertriglyceridemia
    Medical condition: Non Familial Chylomicronemia Syndrome (Non-FCS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-000802-32 Sponsor Protocol Number: CLCQ908B2305 Start Date*: 2012-10-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open label, long-term, safety and tolerability extension to a randomized, double-blind, placebo controlled study of LCQ908 in subjects with Familial Chylomicronemia Syndrome
    Medical condition: Familial Chylomicronemia Syndrome (FCS) (HLP Type I)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004861 10020607 Hyperchylomicronemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003029-11 Sponsor Protocol Number: 2012-489 Start Date*: 2012-09-10
    Sponsor Name:Steen Stender
    Full Title: Ethyl ester Versus Triglyceride formulations of long chained omega-3 fatty acids in moderate hypertriglyceridemia - a randomized placebo-controlled clinical trial (EVT)
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10071235 Combined hyperlipidemia LLT
    15.0 10010331 - Congenital, familial and genetic disorders 10060754 Type IV hyperlipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000437-13 Sponsor Protocol Number: R1500-HTG-20118 Start Date*: 2022-01-07
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
    Medical condition: Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020869 Hypertriglyceridaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-002997-28 Sponsor Protocol Number: ISIS304801-CS20 Start Date*: 2021-03-17
    Sponsor Name:Akcea Therapeutics, Inc.
    Full Title: An Open-Label Study of Volanesorsen (ISIS 304801) Administered Subcutaneously to Pediatric Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10020606 Hyperchylomicronaemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-000493-35 Sponsor Protocol Number: ISIS-304801-CS17 Start Date*: 2016-02-17
    Sponsor Name:Akcea Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Partial Lipodystrophy
    Medical condition: Partial lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10053857 Partial lipodystrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) ES (Completed) NL (Completed) GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003680-10 Sponsor Protocol Number: AROAPOC3-3001 Start Date*: 2022-01-13
    Sponsor Name:Arrowhead Pharmaceuticals, Inc.
    Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome
    Medical condition: Familial Chylomicronemia Syndrome
    Disease: Version SOC Term Classification Code Term Level
    24.1 10010331 - Congenital, familial and genetic disorders 10085051 Familial chylomicronemia syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Trial now transitioned) FR (Trial now transitioned) IE (Trial now transitioned) BE (Trial now transitioned) ES (Ongoing) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003632-23 Sponsor Protocol Number: NI-0501-04 Start Date*: 2016-02-24
    Sponsor Name:NovImmune SA
    Full Title: A Phase 2/3, Open-label, Single Arm, Multicentre Study to Assess Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous Multiple Administrations of NI-0501, an Anti-interferon Gamma (An...
    Medical condition: Haemophagocytic lymphohistiocytosis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10010331 Congenital, familial and genetic disorders SOC
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed) AT (Completed) CZ (Completed) DE (Completed) ES (Prematurely Ended) SE (Completed)
    Trial results: View results
    EudraCT Number: 2021-000138-33 Sponsor Protocol Number: R4461-PLD-20100 Start Date*: 2021-12-21
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A Randomized Double-Blind Placebo-Controlled Study of the LEPR Agonist Antibody REGN4461 for the Treatment of Metabolic Abnormalities in Patients with Familial Partial Lipodystrophy
    Medical condition: Familial Partial Lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10040785 - Skin and subcutaneous tissue disorders 10053857 Partial lipodystrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-003114-10 Sponsor Protocol Number: NI-0501-09 Start Date*: 2018-09-06
    Sponsor Name:Swedish Orphan Biovitrum AG
    Full Title: An Open-label, Single Arm, Multicenter Study to Broaden Access to Emapalumab, an Anti-Interferon Gamma (Anti-IFNγ) Monoclonal Antibody, and to Assess its Efficacy, Safety, Impact on Quality of Life...
    Medical condition: Primary Hemophagocytic Lymphohistiocytosis (pHLH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021428 - Immune system disorders 10071583 Haemophagocytic lymphohistiocytosis PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) IT (Completed) SE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:33:42 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA